IL-13Rα2-specific Allogeneic CAR-T Cells in Recurrent Glioblastoma
Xuetao Li,Xiaoyun Shang,Jiangang Liu,Xuewen Zhang,Xiaoci Rong,Wenjuan Gan,Yu Zhang,Jie Chen,Lin Wang,Zhen Bao,Liang He,Xigang Yan,Yang Liu,Jie Shao,Zongyu Xiao,Zhimin Wang,Zhenhua Zhang,Biao Wang,Bowen Li,Yang Jiang,Haiping Zhu,Zhong Wang,Yuzhang Wu,Yulun Huang
DOI: https://doi.org/10.21203/rs.3.rs-2983817/v1
2023-01-01
Abstract:Abstract BACKGROUND Optimal treatment for recurrent glioblastoma is yet to be definitely established. Development of new therapeutic approaches for recurrent glioblastoma are challenging due to multiple factors, including the immunosuppressive tumor microenvironment, the rapid disease progression, the difficulty for large molecules to cross blood brain barrier, the difficulty of collecting/testing tumor tissues. In the past, intra-ventricular infusion of IL-13Rα2-targeted autologous chimeric antigen receptor-T (CAR-T) cells has shown potent anti-tumor activity in one patient with recurrent glioblastoma. However, patients with malignant glioma often suffer from diminished anti-tumor lymphocyte response, with decreased cell count, exhausted function, or even incompetent in vitro expansion. Allogeneic chimeric antigen receptor (CAR) T cell therapy presents an alternative treatment paradigm and brings new hope for these patients. METHODS We initiated a prospective exploratory study in which MT026, an IL-13Rα2-specific allogeneic universal CAR-T cell preparations, was administered monthly via intra-lumbar injection in patients with IL-13Rα2-positive recurrent glioblastoma until disease progression, unacceptable toxicity, withdrawal of consent, death, loss to follow up, or discontinuation for patients’ benefit at investigator’s discretion. The primary end point was occurrence and severity of adverse events. Secondary end points included overall survival, 12-month survival rate, progression-free survival, objective response rate, duration of response, disease control rate and pharmacokinetic parameters. RESULTS A total of 5 patients, of whom 4 had Karnofsky Performance Scores (KPS) of <70 and only 1 was 90 and all had wild type IDH1/2 and unmethylated MGMT promoter, received MT026 followed by long-term follow-up till the patients’ death. Among the 5 patients, 1 patient (20%) had a complete response and overall survival of up to 17.5 months, 3 patients (60%) had partial responses, and 1 patient (20%) with stable disease, with an overall objective response rate of 80% and disease control rate of 100%. The mean OS was 10.4 months (95% confidence interval [CI], 4.5 to 16.2). The mean PFS was 5.6 months (95% CI, 3.1 to 8.2). The most common treatment-related abnormal laboratory test and symptom were increased cerebrospinal fluid (CSF) interleukin-6 (5/5, 100%) and fever (4/5, 80%), respectively. No adverse events of grade 3 or greater related to MT026 was reported. All the adverse events recovered or were relieved after treatment. No typical or severe cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome occurred. No graft-versus-host disease was observed. MT026 showed an expansion of approximately 1 day and persistence of over 30 days. CONCLUSIONS In patients with recurrent glioblastoma, MT026 resulted in a significantly longer overall survival and a higher objective response rate than history data. MT026 was not associated with any adverse events or toxic effects of grade 3 or higher. (Funded by Chongqing International Institute for Immunology; Chinese Clinical Trial Registry number, ChiCTR2000028801.)